BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9290954)

  • 21. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol.
    Bennett LM; McAllister KA; Malphurs J; Ward T; Collins NK; Seely JC; Gowen LC; Koller BH; Davis BJ; Wiseman RW
    Cancer Res; 2000 Jul; 60(13):3461-9. PubMed ID: 10910057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
    De Benedetti VM; Radice P; Pasini B; Stagi L; Pensotti V; Mondini P; Manoukian S; Conti A; Spatti G; Rilke F; Pierotti MA
    Hum Mutat; 1998; 12(3):215. PubMed ID: 10660329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations.
    Khoo US; Ngan HY; Cheung AN; Chan KY; Lu J; Chan VW; Lau S; Andrulis IL; Ozcelik H
    Hum Mutat; 2000 Jul; 16(1):88-9. PubMed ID: 10874312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population.
    Pääkkönen K; Sauramo S; Sarantaus L; Vahteristo P; Hartikainen A; Vehmanen P; Ignatius J; Ollikainen V; Kääriäinen H; Vauramo E; Nevanlinna H; Krahe R; Holli K; Kere J
    Genet Epidemiol; 2001 Feb; 20(2):239-46. PubMed ID: 11180449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition].
    Ruiz-Flores P; Calderón-Garcidueñas AL; Barrera-Saldaña HA
    Rev Invest Clin; 2001; 53(1):46-64. PubMed ID: 11332051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of BRCA2 gene in sporadic breast tumours.
    Bièche I; Noguès C; Lidereau R
    Oncogene; 1999 Sep; 18(37):5232-8. PubMed ID: 10498873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online.
    Claes K; Machackova E; De Vos M; Mortier G; De Paepe A; Messiaen L
    Hum Mutat; 1999; 13(3):256. PubMed ID: 10090482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients.
    Díez O; Osorio A; Robledo M; Barroso A; Domènech M; Cortés J; Albertos J; Sanz J; Brunet J; SanRomán JM; Alonso MC; Baiget M; Benítez J
    Br J Cancer; 1999 Mar; 79(7-8):1302-3. PubMed ID: 10098775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
    Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific H-Ras minisatellite alleles in breast cancer susceptibility.
    Gosse-Brun S; Sauvaigo S; Daver A; Page M; Lortholary A; Larra F; Bignon YJ; Bernard-Gallon D
    Anticancer Res; 1999; 19(6B):5191-6. PubMed ID: 10697533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC).
    Shen D; Vadgama JV
    Oncol Res; 1999; 11(2):63-9. PubMed ID: 10489161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in BRCA2 expression during progression of the cell cycle.
    Wang SC; Lin SH; Su LK; Hung MC
    Biochem Biophys Res Commun; 1997 May; 234(1):247-51. PubMed ID: 9168997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
    Wang-Gohrke S; Weikel W; Risch H; Vesprini D; Abrahamson J; Lerman C; Godwin A; Moslehi R; Olipade O; Brunet JS; Stickeler E; Kieback DG; Kreienberg R; Weber B; Narod SA; Runnebaum IB
    Br J Cancer; 1999 Sep; 81(1):179-83. PubMed ID: 10487631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
    Rhei E; Bogomolniy F; Federici MG; Maresco DL; Offit K; Robson ME; Saigo PE; Boyd J
    Cancer Res; 1998 Aug; 58(15):3193-6. PubMed ID: 9699640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.
    Shih HA; Nathanson KL; Seal S; Collins N; Stratton MR; Rebbeck TR; Weber BL
    Clin Cancer Res; 2000 Nov; 6(11):4259-64. PubMed ID: 11106241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infrequency of BRCA2 alterations in head and neck squamous cell carcinoma.
    Kirkpatrick H; Waber P; Hoa-Thai T; Barnes R; Osborne-Lawrence S; Truelson J; Nisen P; Bowcock A
    Oncogene; 1997 May; 14(18):2189-93. PubMed ID: 9174054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.
    Ruttledge MH; Sarrazin J; Rangaratnam S; Phelan CM; Twist E; Merel P; Delattre O; Thomas G; Nordenskjöld M; Collins VP
    Nat Genet; 1994 Feb; 6(2):180-4. PubMed ID: 8162072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma.
    Katsama A; Sourvinos G; Zachos G; Spandidos DA
    Cancer Lett; 2000 Mar; 150(2):165-70. PubMed ID: 10704738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
    Beckmann MW; Picard F; An HX; van Roeyen CR; Dominik SI; Mosny DS; Schnürch HG; Bender HG; Niederacher D
    Br J Cancer; 1996 May; 73(10):1220-6. PubMed ID: 8630282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.